Stage
Acquired Unit | AcquiredValuation
$0000About Allergan - U.S. Dermatology Portfolio
Allergan (NYSE: AGN), fka Actavis and before that Watson Pharmaceuticals, is a global pharmaceutical company focused on developing, manufacturing, and commercializing innovative branded pharmaceuticals, high-quality generic, and over-the-counter medicines and biologic products for patients around the world. Allergan markets a portfolio of products that provide treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular, and anti-infective therapeutic categories. Actavis is also engaged in research and development. Watson Pharmaceuticals took on the name Actavis after its 2012 acquisition of the Swiss drug maker of the same name; Actavis later took on the name Allergan after its 2015 acquisition of the American health care company of the same name.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Allergan - U.S. Dermatology Portfolio Frequently Asked Questions (FAQ)
Where is Allergan - U.S. Dermatology Portfolio's headquarters?
Allergan - U.S. Dermatology Portfolio's headquarters is located at Clonshaugh Business and Technology Park, Dublin.
What is Allergan - U.S. Dermatology Portfolio's latest funding round?
Allergan - U.S. Dermatology Portfolio's latest funding round is Acquired Unit.
Who are the investors of Allergan - U.S. Dermatology Portfolio?
Investors of Allergan - U.S. Dermatology Portfolio include Almirall.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
